Evaluation of Esflurbiprofen Patch Adhesion in Healthy Volunteers: An Open-Label Study

The primary objective of this study is to evaluate the **adhesion** of an Esflurbiprofen-containing patch in healthy volunteers. This is clinically relevant as it assesses the patch's ability to remain affixed to the skin, which is crucial for ensuring consistent drug delivery and therapeutic efficacy. The study does not focus on any therapeutic indication, as it is conducted with healthy subjects to specifically assess the patch's adhesion properties.

The clinical trial involves a **patch adhesion trial** with healthy subjects, with no specific therapeutic indication being studied. The study population includes both male and female participants, with an age range categorized as 3, which typically corresponds to adults. The trial population was selected to include a vulnerable population, although specific details regarding the selection process or lifestyle considerations such as diet, physical activity, or habits are not provided. The sponsor has not disclosed the total number of participants involved in the trial. Key inclusion or exclusion criteria are not specified in the available data.

The clinical trial is designed as an **open-label** study to evaluate the adhesion of an Esflurbiprofen-containing patch in healthy volunteers. The trial is categorized under Phase 3 and is not focused on a specific therapeutic indication. The study is expected to commence recruitment on August 1, 2023, and conclude by November 30, 2023. Participants will be involved in the study for the duration of the trial, which spans approximately four months. The trial does not specify a randomized or controlled design, as it primarily aims to assess patch adhesion rather than therapeutic efficacy.

The sequence of study visits includes an initial **screening** visit to determine eligibility based on predefined criteria. Following successful screening, participants will attend scheduled visits to monitor patch adhesion and any potential adverse effects. The frequency and number of follow-up visits are not detailed in the available data. The study will culminate in an end-of-study visit, where final assessments will be conducted to gather comprehensive data on patch adhesion performance.

Participants are expected to remain in the study for its entire duration unless specific conditions necessitate early termination. Such conditions may include adverse reactions to the patch, non-compliance with study protocols, or withdrawal of consent by the participant. The study's primary focus is on the physical properties of the patch, and as such, it does not involve therapeutic interventions or assessments of clinical outcomes related to any medical condition.

No specific information regarding the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, is provided in the available data. Consequently, a detailed description of the experimental treatment cannot be formulated based on the current dataset.

Similarly, there is no information available about any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, used in the study. Therefore, a description of these elements is not possible with the given data.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also absent from the provided data. As such, no further details can be included in this description.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to commence recruitment on August 1, 2023, with an estimated completion date of November 30, 2023. The efficacy assessment will be conducted using predefined parameters, although specific endpoints and methods for measuring efficacy are not detailed in the available data. The trial will follow a structured timeline to ensure systematic data collection and analysis. The study will adhere to rigorous standards typical of Phase 3 trials, focusing on evaluating the treatment's effectiveness in a larger patient population. The trial's design and execution will be aligned with clinical research protocols to ensure the reliability and validity of the efficacy outcomes.